Business Context and Reporting Period
This filing is a Form 10-Q for Brooks Automation, Inc. for the quarter ended December 31, 2020, the first quarter of fiscal 2021. The request identifies Azenta, Inc.; however, the provided filing text identifies the registrant as Brooks Automation, Inc. The company operated through Brooks Semiconductor Solutions Group, Brooks Life Sciences Products, and Brooks Life Sciences Services.
The company provides semiconductor manufacturing automation solutions and life sciences sample-management products and services. The statements are unaudited and presented under U.S. GAAP.
Key Financial Metrics
| Metric | Q1 FY2021 | Q1 FY2020 | Change |
|---|---|---|---|
| Revenue | $249.5 million | $210.5 million | Up 19% |
| Gross profit | $113.1 million | $85.0 million | Up $28.1 million |
| Gross margin | 45.3% | 40.4% | Up 4.9 points |
| Operating income | $30.9 million | $10.7 million | Up 190% |
| Operating margin | 12.4% | 5.1% | Up 7.3 points |
| Income from continuing operations | $27.0 million | $13.2 million | Up $13.8 million |
| Net income | $26.0 million | $13.1 million | Up 99% |
| Diluted EPS | $0.35 | $0.18 | Up $0.17 |
| Cash flow from operations | $43.7 million | $25.7 million | Up $18.0 million |
Revenue by segment was $131.4 million for Semiconductor Solutions, $45.5 million for Life Sciences Products, and $72.6 million for Life Sciences Services. Segment adjusted operating income was $21.5 million, $7.9 million, and $14.3 million, respectively.
At December 31, 2020, cash and cash equivalents were $308.5 million; cash, restricted cash, and marketable securities totaled $322.5 million. Total debt principal was approximately $50.4 million, with $49.6 million recorded as long-term debt and no borrowings under the revolving credit facility. Approximately $47.3 million remained available under the revolver.
Material Changes Versus the Prior Comparable Period
- Revenue increased $39.0 million, led by 53% growth in Life Sciences Products, 17% growth in Life Sciences Services, and 11% growth in Semiconductor Solutions.
- Gross margin expanded primarily because of volume leverage, favorable product and service mix, higher average selling prices in vacuum automation, and improved life sciences operating leverage.
- Operating expenses increased $7.9 million, including increases of $6.7 million in selling, general and administrative expense and $1.7 million in research and development expense. Restructuring charges declined by $0.5 million.
- Income tax expense was $4.8 million compared with a $3.0 million tax benefit in the prior-year quarter. The prior-year benefit included a larger stock-compensation windfall benefit.
- The company acquired Trans-Hit Biomarkers on December 3, 2020 for approximately $15.2 million net of cash acquired. The acquisition added approximately $1.8 million of revenue when combined with the RURO acquisition, compared with the prior-year period.
- Cash flow benefited from stronger earnings and working-capital movements, but investing cash outflows included $15.2 million of capital expenditures and $15.1 million for acquisitions. Financing outflows included $7.4 million of dividends.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide quantitative quarterly or full-year revenue, earnings, or margin guidance.
- Management stated that the COVID-19 pandemic had not substantially negatively affected financial results through the quarter. Life sciences revenue was estimated to have benefited by approximately $10 million and life sciences operating income by approximately $6 million from pandemic-related demand and related effects.
- Management identified continuing risks from customer-demand fluctuations, semiconductor-market cyclicality, supply-chain constraints, employee outbreaks, tariffs and export controls, foreign exchange, competition, technology execution, and regulatory compliance.
- The company expects to incur an additional $43 million to $47 million of capital expenditures over the next four years for its Suzhou, China facility. Total non-cancellable commitments were $187.2 million, including $155.1 million of inventory purchase orders.
- The company recorded a $1.3 million negative adjustment to the gain on the 2019 sale of its semiconductor cryogenics business, resulting in a $0.9 million net loss from discontinued operations. Related indemnification claims remain unresolved, although management does not currently expect a material adverse effect.
- Remaining debt principal payments totaled $50.4 million, including $50.0 million due in fiscal 2025. Debt bears variable interest rates; management estimated that a 100-basis-point rate change would affect quarterly interest expense by approximately $0.1 million.
- The company declared a $0.10-per-share dividend payable March 26, 2021. Future dividends remain discretionary and could be reduced, delayed, or canceled.
- Management stated that there were no material changes to the risk factors disclosed in the fiscal 2020 Form 10-K and that disclosure controls were effective.
Important Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing is for Brooks Automation, Inc., not Azenta, Inc.
- Assess how much of the revenue and margin improvement is recurring versus related to COVID-19 demand, temporary cost benefits, favorable mix, and acquisitions.
- Monitor semiconductor cyclicality, backlog conversion, supply-chain constraints, and the decline in contamination-control revenue.
- Evaluate the execution and funding requirements for the Suzhou facility and the company’s $187.2 million of non-cancellable commitments.
- Review the unresolved Edwards indemnification claims and the potential effect of any losses beyond applicable deductibles, escrow, and insurance.
- Consider exposure to variable-rate debt, foreign exchange movements, goodwill and intangible assets, and the company’s ability to sustain quarterly dividends.